Physician profile
Michael S Gorby
NPI 1366446049
$9,236.19
in general payments reported to CMS, 2019-2025
44 companies · $474 in 2025
The $474 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,821 · 2020: $1,734 · 2021: $2,189 · 2022: $1,486 · 2023: $1,251 · 2024: $282 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,006.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,305.03 | 2019-2023 | Repatha, Otezla |
| Novo Nordisk INC | $896.40 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $864.67 | 2019-2023 | Breztri |
| Lilly USA, LLC | $854.83 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $849.29 | 2019-2025 | Jardiance |
| Pfizer INC. | $593.35 | 2019-2025 | |
| Amarin Pharma, INC. | $432.84 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $431.30 | 2019-2023 | Spravato |
| Mylan Specialty L.P. | $298.01 | 2020-2024 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $294.43 | 2020-2024 | Rexulti |
| Dexcom, INC. | $222.69 | 2021-2023 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Novartis Pharmaceuticals Corporation | $218.19 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $194.33 | 2019-2022 | |
| Glaxosmithkline, LLC. | $179.82 | 2019-2022 | |
| Abbvie INC. | $178.77 | 2021-2025 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gorby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.